Skip to main content

Table 1 Clinical characteristics and treatment response of all patients

From: The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations

Variables All patients Afatinib 30 mg daily Afatinib 40 mg daily P value
N (%) 48 29 19  
Age (year) -mean ± SD 64.6 ± 8.9 67.3 ± 8.0 60.6 ± 8.8 0.0090
Age -n (%)     0.0280
  < 65 years old 26 (54%) 12 (41%) 14 (74%)  
  ≥ 65 years old 22 (46%) 17 (59%) 5 (26%)  
Sex -n (%)     0.0030
 Female 30 (63%) 23 (79%) 7 (37%)  
 Male 18 (38%) 6 (21%) 12 (63%)  
Smoking history -n (%)     0.0509
 Never smoker 43 (90%) 28 (97%) 15 (79%)  
 Ever smoker 5 (10%) 1 (3%) 4 (21%)  
TTF-1 staining -n (%)     
 Positive 47 (98%) 29 (100%) 18 (95%)  
 Not performed 1 (2%) 0 (0%) 1 (5%)  
EGFR gene mutation site -n (%)     0.3720
 Exon19 29 (60%) 19 (66%) 10 (53%)  
 Exon21 19 (40%) 10 (34%) 9 (47%)  
Performance status while starting afatinib -n (%)     0.4861
 ECOG ≤1 38 (79%) 22 (76%) 16 (84%)  
 ECOG ≥2 10 (21%) 7 (24%) 3 (16%)  
Number of metastatic sites on initial diagnosis -n (%)     0.1689
  ≤ 1 site 21 (44%) 15 (52%) 6 (32%)  
  ≥ 2 sites 27 (56%) 14 (48%) 13 (68%)  
Metastatic sites on initial diagnosis -n (%)     
 Brain metastasis 12 (25%) 8 (28%) 4 (21%) 0.6092
 Lung metastasis 14 (29%) 6 (21%) 8 (42%) 0.1104
 Pleural metastasis/pleural effusion 21 (44%) 12 (41%) 9 (47%) 0.6825
 Bone metastasis 28 (58%) 17 (59%) 11 (58%) 0.9602
 Liver metastasis 2 (4%) 1 (3%) 1 (5%) 0.7583
 Adrenal metastasis 7 (15%) 3 (10%) 4 (21%) 0.3040
Weight (kg) -mean ± SD 58.1 ± 9 55.4 ± 9.3 62.2 ± 6.8 0.0091
Height (cm) -mean ± SD 158.9 ± 7.9 156.8 ± 7.6 162.0 ± 7.6 0.0240
Body surface area (m2) -mean ± SD 1.6 ± 0.2 1.5 ± 0.2 1.7 ± 0.1 0.0055
Body mass index (kg/m2) -mean ± SD 23.0 ± 2.9 22.5 ± 3.4 23.7 ± 1.9 0.1332
Serum creatinine level (mg/dL) -mean ± SD 1.1 ± 1.9 1.0 ± 1.7 1.3 ± 2.2 0.6464
eCCr-CG (mL/min) -mean ± SD 74.6 ± 28.4 69.8 ± 25.3 82.1 ± 31.7 0.1439
eGFR-MDRD (mL/min) -mean ± SD 89.9 ± 31.4 89.5 ± 29.7 90.5 ± 34.6 0.9151
Serum albumin (mg/dL) 3.9 ± 0.6 3.8 ± 0.6 4.1 ± 0.5 0.0757
  1. *Abbreviations: eCCr-CG estimated creatinine clearance rate using Cockcroft-Gault formula, eGFR-MDRD estimated glomerular filtration rate using Modification of Diet in Renal Disease formula